non-diabetic control subjects.
1.

Introduction
High blood glucose concentration promotes a variety of reactions, including oxidative stress and formation of advanced glycosylated end products, which have been associated with structural and functional changes in blood vessels that eventually cause dysfunction of several organs, especially the heart, nerves, eyes, and kidneys [1] . Diabetic kidney disease is the most frequent cause of renal failure and end-stage renal disease in developed countries [2, 3] . It is characterized by macroalbuminuria of more than 300 mg/day, progressive decline in glomerular filtration rate (GFR), and hypertension. A considerable number of patients newly diagnosed with type 2 diabetes mellitus may already have developed incipient nephropathy (microalbuminuria) due to a preceding period of undiagnosed diabetes and impaired glucose tolerance. Among the participants of the UK Prospective Diabetes Study (UKPDS), the prevalence of microalbuminuria was 6.5% at diagnosis of type 2 diabetes and approximately 25% ten years after the diagnosis [4] .
Strict glycemic control does not always inhibit the development of nephropathy and other secondary complications of diabetes, whereas even with suboptimal glycemic control, some patients with long disease duration seem not susceptible to microvascular complications [5] . The aim to prevent or delay the onset of microvascular complications has encouraged the search for other factors (e.g. genetic, metabolic, or nutritional), which may predispose to secondary vascular pathology in diabetes mellitus. The role of vitamin B supplementation in preventing microvascular complications of diabetes has already been a focus of research for some years. Studies on vitamin B 6 vitamers (pyridoxamine, pyridoxal 5 0 -phosphate) and high-dose vitamin B 1 suggested inhibition of albuminuria in diabetic animal models [6] [7] [8] . High-dose thiamine has also proofed successful in decreasing urinary albumin excretion in clinical type 2 diabetes [9] . A combined therapy with vitamin B 1 (thiamine) and vitamin B 6 (pyridoxine) in patients with type 2 diabetes and nephropathy significantly decreased glycation of nuclear DNA in leukocytes [10] . The therapeutic benefit of vitamin B supplementation may be achieved through correcting diabetes-related vitamin B deficiencies, which have been observed in experimental diabetes, especially in tissues where vascular complications develop [11] [12] [13] . Evidence for deficiencies of vitamins B 1 and B 12 in both type 1 and type 2 diabetes mellitus have been described in several recent publications [14] [15] [16] [17] [18] . However, data on vitamin B 6 deficiency in patients with type 2 diabetes and on the vitamin B status in diabetic nephropathy are still scarce. The current study was performed to evaluate the vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy. The status of vitamin B 6 was of primary interest.
2.
Materials and methods
Study population
Adults (!18 years) with type 2 diabetes mellitus with a duration of at least 5 years, glycated hemoglobin (HbA1c) <10%
(86 mmol/mol), and a body mass index (BMI) of 19-40 kg/m 2 were recruited through physicians at three general and internal medicine practices in Germany between January and September 2011. At the same time, healthy adults (nondiabetic control subjects) were recruited among office workers, who voluntarily provided information regarding their health situation. For a better representation of the average population, non-diabetic control subjects were also recruited among their relatives and friends. Exclusion criteria were as follows: end stage renal disease with a creatinine clearance of less than 10 mL/min, consumption of more than 50 units of alcohol per week, significant comorbidities, history of renal and/or pancreatic transplant, use of vitamin B supplements (including multivitamin preparations), and participation in an interventional study within 30 days prior to the start of this study. Pregnant or lactating women and women planning to become pregnant were also not recruited. Patients with diabetes were subdivided into two groups based on renal function: patients with microalbuminuria (urinary albumin excretion: 30-300 mg/mg creatinine) and patients without microalbuminuria, i.e. normal urinary albumin excretion (<30 mg/mg creatinine). All patients and control subjects consumed a typical Western European diet, with no special recommendations on food protein content. The study was designed and performed in accordance with the ethical principles stated in the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of the State Chamber of Physicians of Rhineland-Palatinate, Germany. All study participants were informed about the study purposes and plans. Those who agreed to participate gave their written informed consent prior to any investigation.
Blood and urine sampling
Blood and urine samples were taken in the morning after an overnight fast. Venous blood (5 mL) was drawn from patients with diabetes to determine fasting blood glucose (HemoCue Glucose 201+ analyzer, HemoCue AB), HbA1c (high-performance liquid chromatography, immunturbidimetry), and serum creatinine (Jaffé photometric method). The GFR was estimated according to the Modification of Diet in Renal Disease formula. Micral-Test 1 (Roche Diagnostics GmbH) strips were used for semiquantitative assessment of urinary albumin concentrations in diabetic patients. Presence of glucose and total protein in spot urine samples of non-diabetic control subjects were assessed by dipstick tests (Siemens Multistix 10 SG, Siemens Healthcare Diagnostics Ltd.). Blood samples from each patient and control subject were collected in heparinized tubes (5 mL) and in tubes without anticoagulant (10 mL) to determine markers of vitamin B status, lipid metabolism, and hepatic and renal function, Creactive protein (CRP), and soluble vascular cell adhesion molecule-1 (sVCAM-1). Serum or plasma was separated immediately from blood cells by centrifugation for 10 min at 2000 Â g at room temperature; aliquots were snap-frozen and stored at À80 8C until analysis. Spot urine samples (5 mL) were collected from each patient and control subject to determine urinary concentrations of thiamine and vitamin B 6 vitamers. Urine samples were aliquoted, snap-frozen and stored at À80 8C until analysis.
2.3.
Analytical methods
Serum total cholesterol, triglyceride, low density lipoprotein (LDL), and high density lipoprotein (HDL) concentrations were determined by using automated enzymatic colorimetric assays; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined using a standardized UV kinetic method (cobas 1 systems, Roche/Hitachi, Roche Diagnostics GmbH, Mannheim, Germany). Cystatin C, sVCAM-1, and CRP were analyzed by quantitative sandwich enzyme immunoassays (Quantikine 1 , R&D Systems, Abingdon, UK) according to the manufacturer's instructions. Thiamine, thiamine monophosphate (TMP), and thiamine pyrophosphate (TPP) were determined by high-performance liquid chromatography (HPLC, Dionex UltiMate 3000, Thermo Scientific) with fluorimetric detection after precolumn derivatization to the respective thiochromes by using potassium ferricyanide under alkaline conditions [19] . Pyridoxal 5 0 -phosphate (PLP), pyridoxamine 5 0 -phosphate (PMP), pyridoxine, pyridoxamine, pyridoxal, and pyridoxic acid were determined by HPLC (Dionex UltiMate 3000, Thermo Scientific) with fluorimetric detection after postcolumn derivatization using sodium metabisulfite [20] . The stock solutions were calibrated by spectrophotometer using the following molar extinction coefficients (mM À1 cm À1 ):
e 305 = 1.1 (PLP), e 254 = 5.2 (PMP), e 308 = 7.0 (pyridoxine), e 308 = 7.3 (pyridoxamine), e 300 = 5.8 (pyridoxal hydrochloride), and e 316 = 5.1 (pyridoxic acid). Urinary creatinine, plasma methylmalonic acid (MMA), and plasma total homocysteine were determined by using stable isotope dilution analysis liquid chromatography-tandem mass spectrometry as described elsewhere [21] . Vitamin B 12 (cobalamin) was determined by using a competitive chemiluminiscent immunoassay (ADVIA Centaur 1 , Siemens
Healthcare Diagnostics Inc., Tarrytown, NY, USA) and holotranscobalamin (holoTC) was determined by using a microparticle enzyme immunoassay (AxSYM 1 , Axis-Shield Diagnostics, Dundee, UK).
Statistical analysis
The study objectives were analyzed on a per-protocol basis in all participants who had blood and urine samples taken and analyzed. The variable of primary interest was the decrease in plasma PLP levels in patients with type 2 diabetes (with and without microalbuminuria) compared to non-diabetic control subjects. For a statistical power of 0.90, the study group size was determined as N = 52 for significance at the 5% level, assuming a mean plasma PLP concentration of 35 nmol/L (SD 20%) in healthy individuals and an estimated decrease in PLP by 20% in patients with diabetes and microalbuminuria. All other variables were considered secondary and were analyzed in a strictly exploratory manner. Non-parametric methods (two-sided Wilcoxon rank sum test or Fisher's exact test) were used to test for differences in demographic characteristics, vital signs at baseline, and analyte concentrations between patients with diabetes and non-diabetic control subjects, for differences in vitamin B 12 parameters between patients with and without metformin therapy, and for differences in PLP levels between men and women. Pearson's correlation analysis was performed between PLP and age, BMI, and body weight. Statistical analyses were performed using the software SAS 1 for Windows 9.3.1 (SAS Institute Inc., Cary, NC, USA).
Results
Demographic and medical characteristics of the study population
A total of 174 participants, i.e. patients with type 2 diabetes mellitus with and without microalbuminuria and non-diabetic control subjects, were enrolled in this study. Two patients were excluded from the per-protocol analysis due to violation of inclusion criteria. Relevant characteristics of the three study groups are presented in Table 1 . The patients with and without microalbuminuria were similar with regard to age, BMI, smoking history, and alcohol consumption. Control subjects were on average younger than patients with type 2 diabetes. Only 4 patients with diabetes (3.3% of 120 patients) were 50 years of age compared to 34 control subjects (65.4% of 52 subjects). In addition, the majority of the patients, i.e. 103 patients with diabetes (85.8%), were overweight or obese (BMI > 25 kg/m 2 ) compared to 17 control subjects (32.7%).
Alcohol consumption was more frequent in the control group than in the groups with type 2 diabetes ( p < 0.05). Diabetes was well controlled in most patients; the mean HbA1c was 7.3% (corresponding to 65 mmol/mol) in patients with and without microalbuminuria. Mean serum creatinine values and mean GFR did not indicate severe or progressed kidney disease in the patients with type 2 diabetes and microalbuminuria.
The most frequent comorbidities in the patients with diabetes were hypertension and cardiovascular diseases. Medications that may contribute to a vitamin B 12 deficiency (metformin, proton-pump inhibitors, or ACE inhibitors) were used by 33 patients (72%) with and by 50 patients (68%) without microalbuminuria, and by 2 control subjects (4%).
3.2.
Markers of lipid metabolism, liver and kidney function, inflammation, and endothelial dysfunction
The median serum level of total cholesterol was slightly above normal in non-diabetic control subjects but not significantly different compared to the groups with diabetes ( p > 0.05; Table 2 ). Other markers of lipid metabolism were within normal reference ranges in all groups; however, triglyceride levels were higher ( p < 0.0001) and HDL levels were lower ( p < 0.0001) in the diabetes groups than in the control group. Median ALT and AST concentrations were indicative of normal liver function. Cystatin C, a marker of kidney function, was significantly higher in both diabetes groups compared to the control group ( p < 0.0001); in patients with type 2 diabetes and microalbuminuria, median cystatin C level was at the upper limit of the normal reference range. Median serum levels of markers indicating inflammation (CRP) or endothelial dysfunction (sVCAM-1) were increased in both diabetes groups compared to the control group ( p < 0.05). 2 0 1 5 ) 1 5 7 -1 6 5 3.3.
Vitamin B status
The median plasma or serum concentrations of vitamins B 6 , B 1 , and B 12 , their respective vitamers or biomarkers are given in Table 3 . The prevalence of low plasma PLP (<30 nmol/L [22] ) was 63% (N = 29) in the diabetes group with microalbuminuria, 58% (N = 43) in the diabetes group without microalbuminuria, and 25% (N = 13) in the control group. Median plasma concentrations of the vitamin B 6 vitamers PLP, pyridoxine and pyridoxal were significantly decreased in both diabetes groups compared to the control group ( p < 0.0001, all parameters); median PLP was decreased by 43% in patients with microalbuminuria and by 32% in patients without microalbuminuria. On the other hand, median plasma levels of pyridoxamine, PMP, and pyridoxic acid were significantly higher in the diabetes groups than in the control group ( p < 0.001). No significant correlations were found between plasma PLP and age, BMI, or weight in patients with diabetes or in the control group. Significantly higher plasma levels of pyridoxine were found in men compared to women (mean: 42.1 vs. 29.7 nmol/L; p = 0.0134) in the group with diabetes and microalbuminura. In the control group, higher urinary excretion of PMP (mean: 30.1 vs. 19.8 mmol/g creatinine; p = 0.0245) and pyridoxic acid (mean: 30.1 vs. 19.6 mmol/g creatinine; p = 0.0218) was seen in women compared to men. Pyridoxic acid was the major vitamin B 6 metabolite excreted in urine; the excreted amounts of other vitamin B 6 vitamers were small (see Table 4 ). Median urinary pyridoxic acid as a proportion of total urinary vitamin B 6 was significantly higher in patients with diabetes (with microalbuminuria: 75%, p < 0.05; without microalbuminuria: 77%, p < 0.0001) than in non-diabetic control subjects (63%). Compared to the control group, median 
creatinine-corrected urinary pyridoxal levels were decreased in patients with diabetes with or without microalbuminuria by 27% and 17%, respectively ( p < 0.05); and urinary PMP levels were decreased by 82% and 71%, respectively ( p < 0.0001). The prevalence of low plasma thiamine (<70 nmol/L [23] ) was 98% in the diabetes group with microalbuminuria and 100% in the diabetes group without microalbuminuria and in the control group. Nevertheless, the median plasma levels of thiamine were increased by 43% in patients with microalbuminuria and by 44% in patients without microalbuminuria compared to the control subjects ( p < 0.0001). Median TPP levels were also significantly higher ( p < 0.05) while TMP levels were significantly lower ( p < 0.0001) in both groups with diabetes compared to the control group. Median urinary thiamine was lowest in patients with microalbuminuria, but there were no significant differences between the diabetes groups and the control group ( p > 0.05; Table 4 ).
The prevalence of vitamin B 12 deficiency (holoTC 35 pmol/L combined with MMA ! 0.30 mmol/L [24]) was 8.7% (N = 4) in the diabetes group with microalbuminuria, 6.8% (N = 5) in the diabetes group without microalbuminuria, and 5.8% (N = 3) in the control group. The median serum concentrations of vitamin B 12 (cobalamin) and its active form, holoTC, were comparable between the groups with diabetes and the control group ( p > 0.05). Likewise, median plasma concentrations of MMA, a marker of vitamin B 12 deficiency, were similar in the 
Discussion
The results of our study suggest that type 2 diabetes mellitus is associated with decreased plasma PLP concentrations and alterations in vitamin B 6 metabolism, especially in patients with incipient nephropathy. The measured median plasma PLP levels indicated inadequate vitamin B 6 status in patients with type 2 diabetes with and without microalbuminuria, when applying the proposed cutoff level of 30 nmol/L for normal vitamin B 6 status [22] . Indications for lower blood PLP concentrations in type 2 diabetes compared to non-diabetic controls were also found in a small number of previous studies. In patients with type 2 diabetes with and without retinopathy (mean age: approximately 55 years), mean plasma PLP levels were significantly lower compared to the healthy control group [16] . In a Korean study, mean plasma PLP levels were clinically relevantly (if not significantly) decreased in patients (mean age: 50 years) with newly diagnosed type 2 diabetes [25] . In these studies [16, 25] , PLP levels were not indicative of vitamin B 6 deficiency-neither in the groups with diabetes nor in the control groups. In our German study population, the prevalence of PLP < 30 nmol/L was more than twice as high among patients with type 2 diabetes than among control subjects (i.e. 63% and 58% in the groups with and without microalbuminuria vs. 25% in the control group). In other studies, the prevalence of plasma PLP concentrations below the cutoff level was lower, i.e. approximately 10% in US patients with type 1 or type 2 diabetes and sensory polyneuropathy (mean age: 64 years) [26] , and 10% in Korean patients with newly diagnosed type 2 diabetes [25] . In the Korean study, the prevalence of low plasma PLP was approximately 8% in the non-diabetic control group [25] . The more advanced state of the disease (at least a 5-year diagnosis of type 2 diabetes) of the patients in our study may be a possible explanation for the higher prevalence of PLP deficiency compared to the Korean study. Plasma PLP concentrations may be related to age and sex. A survey of PLP status in the US population found that PLP deficiency was more prevalent in elderly men (!65 years) than in younger men; whereas in women, PLP deficiency was most prevalent in the 21-44 years age group [27] . Moreover, differences in dietary habits, including protein intake [28] , blood albumin levels, smoking, alcohol consumption, use of certain drugs, or presence of autoimmune disorders may have an influence on the vitamin B 6 status. We found no correlation between plasma PLP and either age, BMI, or weight and detected no differences between men and women with regard to plasma PLP in any of the study groups. Age and sex were not matched between the control and the diabetes groups in the current study. The study did not include very young participants. Although few differences between men and women were found in urinary vitamin B 6 metabolites, we cannot rule out the source of these differences. Protein intake may be one factor that affects vitamin B 6 requirements. However, patients were not recommended to follow a protein-deprived diet. Therefore, there is no reason to consider dietary protein as an explanation for differences in vitamin B 6 markers between the study groups. Plasma PLP is a commonly used marker to evaluate vitamin B 6 status. Previous studies in diabetic patients have rarely investigated other metabolic forms of vitamin B 6 . Apart from the significantly lower PLP levels in patients with type 2 diabetes, we also observed significantly lower median levels of pyridoxine and pyridoxal, whereas median levels of pyridoxamine, PMP, and pyridoxic acid were significantly higher in the groups with diabetes than in the control group. These results indicate that there may be alterations in the vitamin B 6 metabolic pathways in type 2 diabetes. The underlying mechanisms require further investigation. One potential reason for the higher plasma PMP level may be an enhanced release of PMP from the liver into the blood. Or, PMP may accumulate as a result of a decreased rate of conversion to PLP, a reaction catalyzed by the vitamin B 2 (flavin-mononucleotide)-dependent pyridoxine 5-phosphate oxidase in the liver. The same enzyme also catalyzes the conversion of pyridoxine 5 0 -phosphate to PLP. Whether its function is affected in any way in diabetes is speculative; further evidence is missing as we did not determine pyridoxine 5 0 -phosphate concentrations in this study. Nevertheless, a decreased rate of conversion may contribute to PLP deficiency in type 2 diabetes, independent from dietary intake of vitamin B 6 . We found significantly higher plasma levels of pyridoxic acid (the major end product of vitamin B 6 metabolism) in the patients with diabetes, especially in the group with microalbuminuria. Increased plasma concentrations of pyridoxic acid have previously been found in elderly people and in patients with renal insufficiency [29] [30] [31] . Accumulation of pyridoxic acid may be the result of impaired renal function. However, urinary concentrations of pyridoxic acid were not significantly different in diabetes patients and control subjects. Increased catabolism of PLP is another possible explanation for the accumulation of plasma pyridoxic acid, especially in combination with a decrease in PLP [21, 29] . Possible mechanisms by which vitamin B 6 deficiency may be associated with the development of microalbuminuria and diabetic nephropathy in type 2 diabetes are (1) a potential role of PLP deficiency in inflammatory processes [32, 33] , or (2) through increased blood homocysteine levels [34] . It has been recognized in recent years that inflammatory processes play an important role in the progression of diabetic nephropathy [35, 36] . CRP is a marker of inflammation and a risk predictor for cardiovascular disease [37] . Low plasma PLP was found to be associated with elevated CRP (independent of plasma homocysteine) in an elderly population (Framingham Heart Study cohort) and in nephropathy secondary to type 2 diabetes [32, 38] . In line with this, we found that median CRP was highest in the patients with diabetes and microalbuminuria, which was also the group with the lowest median PLP level. The question whether PLP deficiency directly contributes to the inflammatory process or is a result of it remains unclear. However, current research provides evidence that PLP deficiency is caused by a mobilization of PLP at sites of inflammation and by its increased utilization as a coenzyme in inflammation-related pathways [32, 39] .
Total homocysteine is a proposed biomarker for cardiovascular disease [40] ; elevated plasma levels are associated with inflammation and oxidative stress and thus with endothelial dysfunction [41] . PLP, vitamin B 12 , and folate (vitamin B 9 ) are cofactors in pathways of homocysteine metabolism. Deficiency of one or more of these cofactors results in accumulation of homocysteine [42] . Increased plasma total homocysteine levels have been observed in patients with chronic kidney disease and were associated with nephropathy in type 2 diabetes [43] [44] [45] . In our study, median total homocysteine was not elevated in any of the groups; in fact, the values were rather low compared to the mean homocysteine levels ranging between 9.0 and 15.1 mmol/L found in predominantly middle-aged European populations [46] . Nevertheless, in our study, median homocysteine levels were significantly higher in the patients with diabetes and microalbuminuria than in the control subjects. Possible explanations for the relative increase in homocysteine in this group may include the higher prevalence of low PLP levels or a decreased elimination of homocysteine from the blood due to incipient renal impairment [47] . The median GFR was slightly lower in the patients with microalbuminuria than in the patients without microalbuminuria. Other factors, such as folate status (not determined in this study), age, and gender, may also have influenced the total homocysteine level.
Elevated blood levels of total homocysteine and MMA are sensitive indicators of vitamin B 12 deficiency [48] . Median plasma concentrations of these biomarkers did not differ between patients with type 2 diabetes and the control subjects. The prevalence of functional vitamin B 12 deficiency (e.g. elevated MMA and lowered holoTC) was below 10% in both diabetes groups. In accordance with an earlier report on patients with type 2 diabetes [18] , metformin usage was not associated with significantly higher MMA or total homocysteine in the current study. However, in contrast to the study by Obeid et al. [18] , metformin treatment was associated with only a slight decrease in plasma vitamin B 12 and holoTC, which may be explained by the small sample size or renal insufficiency in the current study (higher creatinine and lower GFR compared to the earlier study [18] ). In contrast to our findings, retinopathy secondary to type 2 diabetes was associated with vitamin B 12 deficiency and elevated levels of plasma total homocysteine, but not with PLP deficiency in an Indian study population [16] . Therefore, diabetes-related comorbidities may affect vitamin biomarkers and add challenge to their diagnoses.
Thiamine is another B vitamin for which low plasma concentrations have been reported in patients with diabetes [14, 49] . Our study confirmed thiamine deficiency in patients with type 2 diabetes, irrespective of whether incipient nephropathy was present or not. An unexpected finding was the even higher level of thiamine deficiency in the nondiabetic control group, since plasma thiamine concentration had been decreased by 75% in patients with type 2 diabetes compared to healthy volunteers in a previous study [14] . Furthermore, vitamin B 1 deficiency is a rare condition in developed countries. Apart from unbalanced diet or certain diseases, alcohol consumption, which was more prevalent in the control group of this study, is usually associated with thiamine deficiency [50] . Low plasma thiamine levels have been linked to an increase in sVCAM-1 (a marker of endothelial dysfunction) in patients with type 1 and type 2 diabetes [14] . Our data do not seem to indicate a direct association between sVCAM-1 and thiamine deficiency. Compared with the nondiabetic control, sVCAM-1 levels were significantly increased in both diabetes groups. Moreover, the median sVCAM-1 level in patients with microalbuminuria was above the upper limit of the normal range, indicating endothelial damage associated with incipient nephropathy.
In conclusion, our study showed that PLP deficiency was prevalent in patients with type 2 diabetes, especially in patients with incipient nephropathy characterized by microalbuminuria. Type 2 diabetes was also associated with other alterations in vitamin B 6 metabolism, including relative increases in PMP and pyridoxic acid, as well as with vitamin B 1 deficiency. Markers of inflammation and endothelial dysfunction may indicate incipient nephropathy in type 2 diabetes. The exact relationships and interactions between vitamin B and inflammation-associated pathways are yet to be discovered. More studies are also needed to clarify the underlying mechanisms that cause deficiency of B vitamins in type 2 diabetes and to evaluate potential benefits and risks of supplementation therapy for the prevention of microvascular complications secondary to diabetes. and Dr. Tanja Henrichs at Syneed Medidata GmbH for statistical and medical writing support, which was funded by Merck KGaA. r e f e r e n c e s
